蟾毒它灵抑制破骨细胞生成并改善雌激素缺乏性骨丢失
本研究探讨中药蟾酥活性成分蟾毒它灵(CS-6)对破骨细胞生成及RANKL诱导信号通路的影响,并在雌激素缺乏小鼠模型中评估其治疗潜力。体外实验显示CS-6剂量依赖性抑制RANKL诱导的破骨细胞形成和骨吸收,降低TRAP、CTSK、DC-STAMP、MMP9及β3整合素基因表达。体内实验表明CS-6可减轻雌激素依赖性骨丢失并降低促炎细胞因子,机制涉及抑制RANKL/TRAF6诱导的NF-κB和ERK/MAPK早期激活,进而抑制c-Fos和NFATc1转录活性。
要点
- CS-6剂量依赖性抑制破骨细胞形成与骨吸收功能。
- CS-6降低破骨细胞相关基因TRAP、CTSK、DC-STAMP、MMP9和β3整合素表达。
- CS-6通过抑制NF-κB和ERK/MAPK通路减少c-Fos和NFATc1转录活性。
核心结论
- 蟾毒它灵(CS-6)具有成为治疗破骨细胞生成和骨吸收增强所致骨溶解性疾病候选药物的潜力。
研究设计与样本
- 研究采用体外破骨细胞生成实验和体内雌激素缺乏小鼠模型,评估CS-6对破骨细胞分化及RANKL诱导信号通路的影响。
主要发现
- 体外实验显示CS-6在破骨细胞生成早期和晚期均剂量依赖性抑制RANKL诱导的破骨细胞形成及骨吸收能力。
- CS-6显著降低破骨细胞相关关键基因TRAP、CTSK、DC-STAMP、MMP9和β3整合素的表达。
- 体内实验表明CS-6可减轻小鼠全身性雌激素依赖性骨丢失并降低促炎细胞因子水平。
- 机制分析提示CS-6抑制RANKL/TRAF6诱导的NF-κB和ERK/MAPK信号通路早期激活,进而抑制c-Fos和NFATc1转录活性。
临床怎么用
- CS-6作为中药蟾酥来源的天然产物,为破骨细胞过度活化相关骨溶解性疾病(如绝经后骨质疏松)提供了潜在治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Osteolytic bone disease is a condition of imbalanced bone homeostasis, characterized mainly by excessive bone-resorptive activity, which could predispose these populations, such as the old and postmenopausal women, to developing high risk of skeletal fragility and fracture. The nature of bone homeostasis is the coordination between the osteoblasts (OBs) and osteoclasts (OCs). Abnormal activation of osteoclasts (OCs) could compromise the bone homeostasis, constantly followed by a clutch of osteolytic diseases, including postmenopausal osteoporosis, osteoarthritis, and rheumatoid arthritis. Thus, it is imperatively urgent to explore effective medical interventions for patients. The traditional Chinese medicine (TCM) gamabufotalin (CS-6) is a newly identified natural product from Chansu and has been utilized for oncologic therapies owing to its good clinical efficacy with less adverse events. Previous study suggested that CS-6 could be a novel anti-osteoporotic agent. Nevertheless, whether CS-6 suppresses RANK-(receptor activator of nuclear factor-κ B ligand)/TRAF6 (TNF receptor-associated factor 6)-mediated downstream signaling activation in OCs, as well as the effects of CS-6 on OC differentiation in vivo, remains elusive. Therefore, in this present study, we aimed to explore the biological effects of CS-6 on osteoclastogenesis and RANKL-induced activation of related signaling pathways, and further to examine the potential therapeutic application in estrogen-deficient bone loss in the mice model. The results of in vitro experiment showed that CS-6 can inhibit RANKL-induced OC formation and the ability of bone resorption in a dose-dependent manner at both the early and late stages of osteoclastogenesis. The gene expression of OC-related key genes such as tartrate-resistant acid phosphatase (TRAP), CTSK, DC-STAMP, MMP9, and β3 integrin was evidently reduced. In addition, CS-6 could mitigate the systemic estrogen-dependent bone loss and pro-inframammary cytokines in mice in vivo. The molecular mechanism analysis suggested that CS-6 can suppress RANKL/TRAF6-induced early activation of NF-κB and ERK/MAPK signaling pathways, which consequently suppressed the transcription activity of c-Fos and NFATc1. Taken together, this present study provided ample evidence that CS-6 has the promise to become a therapeutic candidate in treating osteolytic conditions mediated by elevated OC formation and bone resorption.
引用
- Sun K, Zhu J, Deng Y, et al. Gamabufotalin Inhibits Osteoclastgenesis and Counteracts Estrogen-Deficient Bone Loss in Mice by Suppressing RANKL-Induced NF-κB and ERK/MAPK Pathways. Front Pharmacol. 2021. PMID: 33967763. doi:10.3389/fphar.2021.629968
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。